1Bankfalvi A, Krassort M, Vegh A, et al. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas[J].J Oral Pathol Med,2002;31(8):450
2Kurokawa T, Miyamoto M, Kato K, et al.Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage[J].Br J Cancer,2003;89(6):1042
3Toh Y, Pencil SD, Nicolson GL. Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines[J].Gene,1995;159(1):97.
4Ito H, Hatori M, Kinugasa Y, et al. Comparison of the expression profile of metastasis-associated genes between primary and circulating cancer cells in oral squamous cell carcinoma[J].Anticancer Res,2003;23(2B):1425
5Lo Muzio L, Mignogna MD, Pannone G, et al. The NM23 gene and its expression in oral squamous cell carcinoma [J]. Oncol Rep ,1999;6(4):747.
6Myoung H, Kim MJ, Hong SD, et al. Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma[J]. Cancer Lett,2002;185(2):201.
7Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis[J]. Head Neck,1999;21(7):627.
8Nagata M, Fujita H, Ida H, et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis[J].Int J Cancer,2003;106(5):683
9Maekawa K, Sato H, Furukawa M, et al. Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model[J].Clin Exp Metastasis,2002;19(6):513
10Shang ZJ, Li JR, Li ZB. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma[J].Int J Oral Maxillofac Surg,2002;31(5):495
2Folkman J. Angiogenesis research: from la .bortory to clinic []. Forum Genova. 1999.9(3): 59~62.
3Fang J, Shing Y, Wienderschain D, et al. Matrix metalloproteinase- 2 is required for the swich to the angiogenic phenotype in a tumor model [J]. Proc Natl Acad Sci USA,2000, 97(21): 3884--3889.
4Nomura H, Fujirnoto H, Seiki M, et al. Enhanced Production of Matrix metalloproteinase and activation of Matrix metalloproteinase -2 (gelatinase A) in human gastric carcinomas[J]. Int J Cancer,1996,69(1): 9-16.
5Charous S, Stricklin GP, Narmey LB, et al. Expression of matrix metallotrtoteinase and tissue inhibitor of metalloproteinase in head and neck squamous cell carcinoma[J]. Am Otol Rhinol Larygol, 1997,106(3) : 271 --277.
6Sustinen M, Kainulainen T, Hurskainen T, et al. Expression of matrix metalloproteinases (MMP - 1 and - 2) and their inhibitors(TIMP - 1, - 2, and - 3 ) in oral lichen planus, dysplasia, oral squamous and lymph node metastasis[J]. Br J Cancer, 1998, 77(12) : 2239-2245.
7Weidener N, Folkman J, Poc.za F, et al. Tumor angiogenesis: a new significant and independent indicator in early stage breast carcinoma[J]. J Natl Cancer Inst, 1992, 84(10): 1875--1887.
8Dameron M, Volpert V, Tainsky A, et al. Control of angiogenesis in fibroblasts by P53 regulation of thrombospondin- 1 [ J ]. Science,1994,265(8) : 1582-1584.
9Rothenberg ML, Nelson AR, Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors[J]. Stem cells, 1999, 17(3): 237--240.
